The sphingosine-1-phosphate receptor: A novel therapeutic target for multiple sclerosis and other autoimmune diseases

Clin Immunol. 2017 Feb:175:10-15. doi: 10.1016/j.clim.2016.11.008. Epub 2016 Nov 23.

Abstract

Multiple sclerosis (MS) is a prototype autoimmune disease of the central nervous system (CNS). Currently, there is no drug that provides a cure for MS. To date, all immunotherapeutic drugs target relapsing remitting MS (RR-MS); it remains a daunting medical challenge in MS to develop therapy for secondary progressive MS (SP-MS). Since the approval of the non-selective sphingosine-1-phosphate (S1P) receptor modulator FTY720 (fingolimod [Gilenya®]) for RR-MS in 2010, there have been many emerging studies with various selective S1P receptor modulators in other autoimmune conditions. In this article, we will review how S1P receptor may be a promising therapeutic target for SP-MS and other autoimmune diseases such as psoriasis, polymyositis and lupus.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Autoimmune Diseases / metabolism*
  • Central Nervous System / metabolism
  • Humans
  • Lysophospholipids / metabolism*
  • Multiple Sclerosis / metabolism*
  • Multiple Sclerosis, Chronic Progressive / metabolism
  • Receptors, Lysosphingolipid / metabolism*
  • Sphingosine / analogs & derivatives*
  • Sphingosine / metabolism

Substances

  • Lysophospholipids
  • Receptors, Lysosphingolipid
  • sphingosine 1-phosphate
  • Sphingosine